Most Read Articles
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
5 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 18 Jul 2018
Use of proton pump inhibitors and histamine‐2 receptor antagonists appears to reduce the risk of developing oesophageal carcinoma in patients with Barret’s oesophagus, according to a study.

Elderly chronic hepatitis C patients benefit from DAAs

06 Nov 2019

Direct-acting antivirals (DAAs) are effective for chronic hepatitis C even in elderly adults, resulting in respectable rates sustained virological response (SVR) independently of age, a recent study has shown.

Researchers retrospectively examined 1,151 elderly chronic hepatitis C patients who were further disaggregated according to age: 65 years (mean age, 70.85±5.47 years; 59.1 percent male) and <65 years (mean age, 54.06±9.37 years; 62.4 percent male). Comparative DAA efficacy was the primary outcome.

The treatment response rate in the overall cohort was 97.7 percent. This was slightly higher in the younger subgroup (98.3 percent vs 97.1 percent), though the difference was not statistically significant. Twenty-six patients failed treatment; 15 belonged to the older group.

SVR rates 12 weeks after treatment (SVR12) were 97.4 percent, 97.2 percent and 86.7 percent for the 65–74-years, 75–84-years and 85-years age groups, respectively. No between- and among-group differences were reported.

Multivariate logistic regression analysis revealed that the combination of DAAs received (p0.001) and coinfection with HIV (p=0.001) were the only significant predictors of SVR12. Both factors were also initially predictive of treatment response in the older subgroup, though their respective significance were attenuated upon multivariable analysis.

Other variables, such as comorbidities, fibrosis stage, baseline viral load, previous treatment history and demographic factors, were all unrelated to the likelihood of treatment response.

“Treatment should not be withheld purely on the grounds of advanced age, and older age should not be a barrier to [hepatitis C virus] treatment,” said researchers. “Older adults should have the opportunity to benefit from the high cure rates and health benefits associated with viral eradication.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
5 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 18 Jul 2018
Use of proton pump inhibitors and histamine‐2 receptor antagonists appears to reduce the risk of developing oesophageal carcinoma in patients with Barret’s oesophagus, according to a study.